Letter from Taj Pharma CEO and Leadership Team COVID-19

Letter from Taj Pharma CEO and Leadership Team COVID-19

Dear Colleagues/ Agents / Distributors,

Taj Pharma CEO and Leadership

The growing outbreak of COVID-19 has affected each one of us in multiple ways, our families, friends, businesses and way of life. This fast-changing situation has forced us to re-evaluate how we operate. At Taj Pharmaceuticals, we are working on using this challenge as an opportunity to make our company more dedicated, more efficient, and more focused on serving the needs of our clients, a better company to partner with in our common mission of bringing healthcare treatments to market faster and of improving outcomes for patients. To manage through the crisis, we have established a new agile generics supply governance cadence. Our CEO Generics Supply Center meets daily at 4 p.m. EDT and maintains coordination with each of our Global Business Unit and Regional level Generics Supply Centers, as well as our Medical & Scientific Task Force, IT Task Force, HR Task Force and Finance Task Force. In this letter, we would like to update you as a leadership team on how we are managing this crisis and helping the healthcare industry respond to its challenges.

Putting safety first. Our first priority is the safety of staff and the patients, healthcare professionals, customers and suppliers we frequently interact with. To limit exposure, we have prohibited international travel, closed facilities and asked most of our staff to work remotely. We have added bandwidth and VPN capacity to our advanced infrastructure to avoid service disruptions. To date, this transition has gone smoothly. Our data production centers remain fully operational and our technology, analytics, primary market research and real-world deliveries continue in the ordinary course per existing business continuity plans.

Minimizing disruption to clinical trials. As supply chains are disrupted, as clinics and hospitals become inaccessible or as it becomes sometimes unsafe or difficult for patients to travel, we are doing everything in our power to ensure science and innovation do not stop. The situation is fluid and we have been monitoring daily, and sometimes hourly, each trial, each site, each enrolled patient, to maintain the integrity of our ongoing trials. We are coordinating closely with local health authorities and customers to deploy, when appropriate and feasible, our services and technologies to further increase remote-based CRA and centralized monitoring for trials, remote patient visits (aka virtual trials), supply logistics and other remote interactions between patients and HCPs. We are currently transitioning significant portions of trials to our Study Hub Virtual Trial execution platform, including Televisit, digital interaction and more, to enable study continuity on a global basis.

Helping organizations plan & manage for the outbreak. We are applying our people, data and technology, to bring AI and insights to help accelerate responses and planning efforts. We have provided data scientists with information and tools to understand the rapidly evolving dynamics of the outbreak to predict how things will develop. We are rolling out new remote-detailing solutions and workflows to support remote-based working. In Japan and Italy, for example, we are creating AI-powered forecasting tools that are helping predict the progression of COVID-19 — this will expand to other countries in Europe soon. In the UK, we are providing analytics and staff who are physically working side-by-side with government officials to help monitor the drug supply chain. And in the India, we are working with key central agencies to provide data and insights that will help them manage capacity and demand across the health system.

Helping accelerate the development of COVID-19 treatments and vaccines. Lastly, we are joining the global response to the crisis and contributing our resources to its resolution by providing Taj Pharmaceuticals staff, technology and expertise to support the development of new treatments. In Asia, we are providing an Taj Pharmaceuticals team to help develop two new treatments for COVID-19 using existing HIV and flu vaccines. In India, we are partnering with academic institutions to develop new lab tests to identify vaccine candidates quicker than currently available tests. And in Europe, we are collaborating with governments and the pharmaceutical industry to develop several experimental vaccine candidates using our Prime Site networks and data assets to accelerate timelines. If successful, all of these will bring much-needed treatments to patients quickly.

We would like to end this letter with a message there is light at the end of the tunnel. This outbreak is extraordinary in terms of scale, speed, and uncertainty but there is reason to be optimistic. The Chinese National Health Commission recently reported almost no new domestic cases, approximately 60% of hospitals outside of Hubei Province are now accessible to patients, schools are slowly reopening and life beginning to normalize. Even with the recent turmoil, we are still expecting growth in the Chinese pharmaceutical market this year. Given all these signs, we are hopeful that by end of May, China will almost fully recover. You will find our latest update, insights and analysis on the situation in China by clicking HERE.

In these most unusual of circumstances, Taj Pharmaceuticals is renewing its commitment to becoming a better partner to you, to marshal all our talents and resources at the service of the greater cause we all work for, to benefit the health and wellbeing of patients everywhere. We will continue be here to help you accomplish this objective during and after this crisis is over. Please do not hesitate to call on any one of us for any reason. We wish you and everyone around you the best of health and look forward to meeting and engaging with you and your teams in-person soon.

Stay safe, stay healthy, stay in touch.

Warm regards,

Abhishek Kumar Singh
CEO — Taj Pharma Group
Taj Pharmaceuticals Limited
Help Line: +91 8448444095
Toll Free No: 1800–222–434 (Ext 3 International Dept.)


As the global situation around coronavirus (COVID-19) continues to evolve we wanted to share with you the steps Taj Pharmaceuticals is taking to ensure the well being of our customers, team members and the wider community.

Whilst the number of reported cases in India is still relatively low, we have implemented the following precautionary measures:

  • Work spaces are being regularly disinfected and sanitized
  • Body temperatures are checked as employees enter office
  • Hand sanitizer is available to all on office premise
  • All employees are asked to wear mask at all times
  • Work from home has been given to those employees where possible
  • All outstation travels, personal meetings & visits have been restricted
  • Employees have been educated regarding regular hand washing, avoiding close contact with others (particularly those with flu-like symptoms) and self-isolating if symptoms present themselves
  • We continue to actively monitor and act on all health and travel advice issued by Indian and relevant global governments and health departments

We will continue to observe caution and play our part in limiting the spread of the infection. Taj Pharmaceuticals Limited wishes you and everyone, good health and safety.

The health and safety of our employees, clients, and candidates is of utmost importance to PSI. We have an internal task force that now meets each business day to monitor the situation with Novel Coronavirus (COVID-19), and we are in close communication with our testing partners around the world.

COVID-19: Updates for Our Customers


As the novel coronavirus (COVID-19) situation continues to evolve and business impacts are becoming more far reaching across every sector, I wanted to share what we are doing at Taj Pharmaceuticals to ensure the continuity in our support of you and the animals in your care. Read more


At this time, there is no direct impact to Taj Pharmaceuticals supply, and we continue to monitor closely with distributors.

  • If the situation evolves, we have a robust 4–6 months inventory on key products.
  • Border controls are evolving along with the situation, region by region. Taj Pharmaceuticals has a well-established process to assess and act quickly on these developments and restore operations to normal levels and mitigate further impact to the business.
  • Taj Pharma is monitoring all cargo movements and transportation lanes to ensure successful movement of goods throughout our network.

At this time, all of our manufacturing sites around the world remain open. With the health and safety of our colleagues as our top priority, we are taking great care to ensure continuity at all our manufacturing sites.

  • If we need to close a site, Taj Pharmaceuticals will leverage its global network and work proactively to ensure manufacturing capabilities meet customer needs.
  • We are complying with all local government recommendations for social distancing with flexible work arrangements.

Across our global network, formal plans are underway within our Global Manufacturing & Supply team to bolster our inventory and availability through:

  • Increased inventory positions for all aspects of our supply chain: Finished Goods, Active Ingredients and supporting components.
  • Deployment of inventory from regional hubs to market-specific warehouses.

Our field sales and technical representatives are available remotely.

  • If you require an in-person visit from one of our representatives, please be assured they are following the health and hygiene guidance from the World Health Organization and Centers for Disease Control and Prevention.
  • If you work with a Taj Pharmaceuticals representative, please reach out to him or her as your first point of contact. Otherwise, please contact us here.



According to the World Health Organization and the U.S. Centers for Disease Control & Protection, there is no evidence that companion animals or pets such as cats and dogs can spread the virus that causes COVID-19.

Infectious disease experts and multiple international and domestic human and animal health organizations agree there is no evidence at this point to indicate that pets can become ill with COVID-19 or spread COVID-19 to people or other animals. (AVMA)

If a person becomes ill with COVID-19, out of an abundance of caution, WHO and CDC recommend limited contact with animals and that another member of the household take care of walking, feeding, and playing with pets. If an ill person must care for pets or has a service animal, it is recommended that they wear a facemask; don’t share food, kiss, or hug them; and that they practice handwashing before and after contact with pets.

For more information on risk to companion animals, read the statement from the World Small Animal Veterinary Association.


According to the Friedrich Loeffler Institute (FLI), the National Institute for Animal Health in Germany, there is currently no evidence that farm animals can contract the SARS-CoV-2 coronavirus (COVID-19) or that livestock can transmit and spread it.


Public health officials and academics agree that the coronavirus poses little danger from a foodborne illness perspective. (Food Safety News)

Coronaviruses are generally thought to be spread from person-to-person through respiratory droplets. Currently there is no evidence to support transmission of COVID-19 associated with food. Before preparing or eating food it is important to always wash your hands with soap and water for 20 seconds for general food safety. Throughout the day wash your hands after blowing your nose, coughing or sneezing, or going to the bathroom. (CDC)

What Taj Pharmaceuticals is Doing

Through the Taj Pharma Center for Transboundary and Emerging Diseases, our infectious disease scientists are evaluating technical reports in this rapidly evolving situation to understand if the novel coronavirus is a specific risk to livestock and pets. In response to outbreaks of infectious diseases, the Center mobilizes resources from across our company and works closely with leaders from government, health organizations and the veterinary and livestock agricultural communities to identify disease threats to animals. The Center harnesses our capabilities in vaccine development, alliances with centers of excellence, regulatory affairs and flexible manufacturing capacity.


Since the outbreak began in early January, we have maintained a coordinated response across our global sites to prioritize the safety of our colleagues, the service of our customers, and the quality of our products. Caring for our colleagues is our top priority because we know they make all the difference to customers and we depend on them to deliver our medicines and products. We are following the health guidance of the World Health Organization and the Centers for Disease Control and Prevention at our sites and providing that guidance to our colleagues. We are being flexible with our work and implementing remote and staggered schedules where appropriate, as well as offering colleagues the flexibility to care for their health and families.

Taj Pharmaceuticals Closures

As the COVID-19 outbreak continues to spread throughout the communities where we live and work, in order to continue to help protect the health and safety of our candidates, clients, and employees, we have made the difficult decision to temporarily close our owned and operated physical manufacturing units in India starting end of day March 19, and in the United Kingdom starting end of day March 20, until April 13.

We also continue to monitor all our partner sites around the world and adhere to closures based on country and local requirements.


Effective immediately, candidates can reschedule up to and including the day of testing at no penalty and no documentation required. NOTE: In most cases, candidates can reschedule their examinations on-line and they are encouraged to do so. If a candidate chooses to reschedule through our candidate support call centre, they may experience longer than usual wait times under the current circumstances.

Candidates that are a part of an eligibility programme will be provided guidance if a new eligibility is required in order to reschedule and how to obtain it.

We are obtaining guidance from our client to support candidates who must test within a specified period and how we are able to accommodate them.

  • All reschedule rules and no show policies are relaxed through April 30th.
  • If you are unable to make your exam and you are reported as a no-show you will be allowed to reschedule at no cost.
  • In the event that there are restrictions based on eligibility periods or test windows we will work on options with your examination sponsor.’

The week of March 21st, a guest at our hotel preliminarily tested positive for COVID-19. With 21c’s first priority first being the safety of our team, our guests and our community, we did temporarily shut down the company, units, and labs. During this shutdown, we completed a comprehensive, company-wide deep clean with a third party company. With the deep clean complete, we re-opened our doors on March 31st.

The Company Taj Pharmaceuticals will continue to work with a global team of experts in hygiene and safety, heightening our already vigorous hygiene and prevention measures, with enhanced cleaning procedures and EPA-registered disinfection products with proven efficacy in killing respiratory viruses, including COVID-19.

Taj Pharmaceuticals : Our commitment to clients in the spread of COVID-19

Taj Pharmaceuticals : Our commitment to clients in the spread of COVID-19

We Taj Pharmaceuticals are in the midst of challenging times, brought upon us due to the unimaginable spread of COVID-19. As we grapple with this difficult and ever evolving situation, we wanted to reach out to make sure that you are doing okay and in case you needed any help. It is hard to think of a business that is not impacted by this pandemic, the effects of which we will all continue to feel for a long time.

As a firm, we have always placed the highest emphasis on delivering quality generics to all our clients, consistently. I want to take this opportunity to assure you that our professional commitments continue to occupy an important place for all of us at Taj Pharmaceuticals even as we steer our way through the crisis. Our Values of Care and Working Together come to fore in difficult times like these — we want to be responsible towards you, as well as our people and the larger society that we are a part of.

We Taj Pharmaceuticals have put in place several measures that are helping us address this situation. Earlier this week, we announced that our people would work from home until further notice or unless there is a critical business need. We have also discontinued all international travel and physical meetings for the time being.

We Taj Pharma have been able to make this decision on the back of a robust infrastructure and processes that we have put in place over the past few years, which enable us to continue providing seamless service to our clients without the need to be physically present in office. Accordingly, we are also working with our clients to assess where our teams can be moved to a virtual working space.

I want to give you the confidence that we have tested our Business Continuity processes and at no time, do our clients need to be concerned about our ability to service them seamlessly.

In this difficult time, we have witnessed some heartening examples of enduring human spirit and this gives me the belief that together we will overcome this.

I thank you for your continued support and we at Taj Pharmaceuticals, assure our continued support to you and your teams as we together navigate these challenging times.

Take care and stay safe.

Warm regards,

Abhishek Kumar Singh
CEO| Taj Pharmaceuticals India